Education
About Us
Working with TipRanks
Follow Us
Benitec Biopharma (BNTC)
NASDAQ:BNTC
BNTC Stock Chart & Stats
$10.98
<$0.01(0.09%)
At close: 4:00 PM EST
$10.98
<$0.01(0.09%)
Day’s Range― - ―
52-Week Range$9.85 - $17.15
Previous CloseN/A
Volume10.71K
Average Volume (3M)204.01K
Market Cap
$384.42M
Enterprise Value$105.90M
Total Cash (Recent Filing)$188.79M
Total Debt (Recent Filing)$987.00K
Price to Earnings (P/E)―
Beta0.42
Next Earnings
May 18, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding34,354,336
10 Day Avg. Volume242,638
30 Day Avg. Volume204,012
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)4.35
Price to Sales (P/S)0.00
P/FCF Ratio-17.95
Enterprise Value/Market Cap0.28
Enterprise Value/Revenue190.47
Enterprise Value/Gross Profit-1.60K
Enterprise Value/Ebitda-2.06
Forecast
1Y Price Target
$32.00Price Target Upside191.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Early Clinical EfficacyAll completers in the initial cohort were classified as responders under the trial's predefined responder criteria, indicating consistent improvement across patient-reported symptoms and functional swallowing tests.
Financial FlexibilityAnalyst assesses the company's cash position as sufficient to fund the BB-301 clinical program and initiate a registrational trial, with interim data enabling equity funding that improved financial flexibility.
Regulatory PathwayRegulatory alignment with the FDA on pivotal trial design, together with Fast Track and Orphan Drug designations, strengthens the pathway toward potential approval for BB-301.
Bears Say
Limited Patient SampleOnly a small number of patients have been dosed, limiting the strength of efficacy evidence and reducing statistical reliability of current results.
Need For Confirmatory DataPositive outcomes observed in a limited group of patients require additional data to confirm durability and generalizability of the treatment effect.
Rising Operating ExpensesRising research and administrative costs driven by higher share-based compensation increase operating cost pressure and could shorten the company runway if expense trends persist.
Benitec Biopharma News
BNTC FAQ
What was Benitec Biopharma’s price range in the past 12 months?
Benitec Biopharma lowest stock price was $9.85 and its highest was $17.15 in the past 12 months.
What is Benitec Biopharma’s market cap?
Benitec Biopharma’s market cap is $384.42M.
When is Benitec Biopharma’s upcoming earnings report date?
Benitec Biopharma’s upcoming earnings report date is May 18, 2026 which is in 55 days.
How were Benitec Biopharma’s earnings last quarter?
Benitec Biopharma released its earnings results on Feb 12, 2026. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.223 by -$0.037.
Is Benitec Biopharma overvalued?
According to Wall Street analysts Benitec Biopharma’s price is currently Undervalued.
Does Benitec Biopharma pay dividends?
Benitec Biopharma pays a Notavailable dividend of $0.765 which represents an annual dividend yield of N/A. See more information on Benitec Biopharma dividends here
What is Benitec Biopharma’s EPS estimate?
Benitec Biopharma’s EPS estimate is -0.28.
How many shares outstanding does Benitec Biopharma have?
Benitec Biopharma has 34,354,336 shares outstanding.
What happened to Benitec Biopharma’s price movement after its last earnings report?
Benitec Biopharma reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.223. Following the earnings report the stock price went down -2.661%.
Which hedge fund is a major shareholder of Benitec Biopharma?
Currently, no hedge funds are holding shares in BNTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Benitec Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.00 (191.44% Upside)
$32.00 (191.44% Upside)
Blogger Sentiment
Bullish
BNTC Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.60%
12-Months-Change
Fundamentals
Return on Equity
-38.92%
Trailing 12-Months
Asset Growth
141.16%
Trailing 12-Months
Company Description
Benitec Biopharma
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
BNTC Stock 12 Month Forecast
Average Price Target
$32.00
▲(191.44% Upside)
Technical Analysis
Tvardi Therapeutics
―
Assembly Biosciences
―
Rocket Pharmaceuticals
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―
Ownership Overview
5.76% Insiders
7.28% Mutual Funds
61.38% Other Institutional Investors
19.34% Public Companies and
Individual Investors